The PSI has collected data on counterfeiting, illegal diversion, and theft incidents for twenty-one consecutive years. The yearly totals for the last five years are shown in the line graph below.
The graph shows:
There were 6,615 pharmaceutical crime incidents in CY 2022
Incidents increased by ten percent (+10%) from CY 2021
To gauge the magnitude of these counterfeiting incidents, the PSI continued to track the quantity of drugs seized. Incidents involving the seizure of more than 1,000 dosage units were classified as a commercial incident; incidents involving less than 1,000 dosage units were classified as non-commercial.
The Institute found:
Seizures increased by forty-seven percent (+47%) over the prior year
Commercial seizures represented seventy-one percent (71%) of the total
Nineteen percent (19%) of the seizures were non-commercial.
While non-commercial size seizures worldwide vastly outnumber commercial size seizures, the PSI focuses on the documentation of organizations engaged in pharmaceutical crime. As most non-commercial size seizures of illegal pharmaceuticals are intended for personal use, they are not counted among PSI incident data unless a specific criminal network is identified.